{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:32:43Z","timestamp":1787592763306,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Corticosteroids are widely used to prevent and treat chemotherapy-induced nausea and vomiting (CINV) due to their pleiotropic biological effects. However, concerns have been raised about their immunosuppressive properties when combined with immunotherapy. Specifically, their potential impact on the efficacy of immunotherapy, mainly immune checkpoint inhibitors (ICIs), remains a subject of debate. This manuscript discusses the mechanisms by which corticosteroids mitigate CINV, the challenges associated with their concurrent use with immunotherapy, and emerging therapeutic strategies evaluating dexamethasone-free regimens. A careful balance must be struck in corticosteroid use to effectively manage CINV while optimizing the outcomes of immunotherapy.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf045","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:22:42Z","timestamp":1743459762000},"source":"Crossref","is-referenced-by-count":11,"title":["Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-3855","authenticated-orcid":false,"given":"Alessandro","family":"Ottaiano","sequence":"first","affiliation":[{"name":"SSD-Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione \u201cG. Pascale,\u201d 80131 Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Santorsola","sequence":"additional","affiliation":[{"name":"SSD-Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione \u201cG. Pascale,\u201d 80131 Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Capuozzo","sequence":"additional","affiliation":[{"name":"Coordinamento Farmaceutico , ASL-Naples-3, 80056 Ercolano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Scala","sequence":"additional","affiliation":[{"name":"Microenvironment Molecular Targets, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione \u201cG. Pascale,\u201d 80131 Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2025033118434150400_CIT0001","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol."},{"key":"2025033118434150400_CIT0002","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol."},{"key":"2025033118434150400_CIT0003","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12032-023-02280-7","article-title":"Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies","volume":"41","author":"Raghani","year":"2024","journal-title":"Med Oncol."},{"key":"2025033118434150400_CIT0004","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/25785826.2020.1785654","article-title":"Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy","volume":"44","author":"Nakajima","year":"2021","journal-title":"Immunol Med."},{"key":"2025033118434150400_CIT0005","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/17425255.2016.1225038","article-title":"Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review","volume":"12","author":"Boudou-Rouquette","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2025033118434150400_CIT0006","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2015.09.005","article-title":"Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant\/palonosetron)","volume":"41","author":"Rojas","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"2025033118434150400_CIT0007","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/1469-8986.3940491","article-title":"Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea","volume":"39","author":"Morrow","year":"2002","journal-title":"Psychophysiology."},{"key":"2025033118434150400_CIT0008","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","article-title":"GDF15 Induces Anorexia through Nausea and Emesis","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Metab."},{"key":"2025033118434150400_CIT0009","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s1072-7515(02)01491-6","article-title":"Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications","volume":"195","author":"Holte","year":"2002","journal-title":"J Am Coll Surg."},{"key":"2025033118434150400_CIT0010","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/bjs.6744","article-title":"Randomized clinical trial of the effect of glucocorticoids on peritoneal inflammation and postoperative recovery after colectomy","volume":"96","author":"Zargar-Shoshtari","year":"2009","journal-title":"Br J Surg."},{"key":"2025033118434150400_CIT0011","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and cancer immunotherapy","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2025033118434150400_CIT0012","doi-asserted-by":"publisher","first-page":"493","DOI":"10.6004\/jnccn.2012.0049","article-title":"Corticosteroids in the treatment of chemotherapy-induced nausea and vomiting","volume":"10","author":"Barbour","year":"2012","journal-title":"J Natl Compr Canc Netw."},{"key":"2025033118434150400_CIT0013","doi-asserted-by":"publisher","first-page":"e14583","DOI":"10.1200\/JCO.2021.39.15_suppl.e14583","article-title":"Corticosteroid use and its impact on the efficacy of immunotherapy in multiple tumor types","volume":"39","author":"Nelson","year":"2021","journal-title":"JCO"},{"key":"2025033118434150400_CIT0014","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol."},{"key":"2025033118434150400_CIT0015","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med Oncol."},{"key":"2025033118434150400_CIT0016","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.89.21.9991","article-title":"A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1","volume":"89","author":"Cronstein","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"2025033118434150400_CIT0017","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More than suppression: glucocorticoid action on monocytes and macrophages","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Front Immunol."},{"key":"2025033118434150400_CIT0018","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1600-6143.2006.01270.x","article-title":"Immunosuppression: evolution in practice and trends, 1994-2004","volume":"6","author":"Meier-Kriesche","year":"2006","journal-title":"Am J Transplant."},{"key":"2025033118434150400_CIT0019","doi-asserted-by":"publisher","first-page":"19896","DOI":"10.1074\/jbc.RA119.010379","article-title":"Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells","volume":"294","author":"Maeda","year":"2019","journal-title":"J Biol Chem."},{"key":"2025033118434150400_CIT0020","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jama.1963.03710020036011","article-title":"A controlled clinical evaluation of antiemetic drugs","volume":"186","author":"Moertel","year":"1963","journal-title":"JAMA."},{"key":"2025033118434150400_CIT0021","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM198110153051601","article-title":"Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting","volume":"305","author":"Gralla","year":"1981","journal-title":"N Engl J Med."},{"key":"2025033118434150400_CIT0022","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJM198408303110901","article-title":"Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy","volume":"311","author":"Markman","year":"1984","journal-title":"N Engl J Med."},{"key":"2025033118434150400_CIT0023","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1056\/NEJM198102193040815","article-title":"Methylprednisolone as an antiemetic","volume":"304","author":"Lee","year":"1981","journal-title":"N Engl J Med."},{"key":"2025033118434150400_CIT0024","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM198108273050914","article-title":"Dexamethasone as an antiemetic in patients treated with cisplatin","volume":"305","author":"Aapro","year":"1981","journal-title":"N Engl J Med."},{"key":"2025033118434150400_CIT0025","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archinte.1983.00350070063012","article-title":"Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy","volume":"143","author":"Cassileth","year":"1983","journal-title":"Arch Intern Med."},{"key":"2025033118434150400_CIT0026","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199501053320101","article-title":"Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer","volume":"332","author":"Italian Group for Antiemetic Research","year":"1995","journal-title":"N Engl J Med."},{"key":"2025033118434150400_CIT0027","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1345\/aph.1E242","article-title":"Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting","volume":"39","author":"Massaro","year":"2005","journal-title":"Ann Pharmacother."},{"key":"2025033118434150400_CIT0028","doi-asserted-by":"publisher","first-page":"oyae233","DOI":"10.1093\/oncolo\/oyae233","article-title":"Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials","volume":"16","author":"Luo","year":"2024","journal-title":"Oncologist."},{"key":"2025033118434150400_CIT0029","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025033118434150400_CIT0030","doi-asserted-by":"publisher","first-page":"e2300301","DOI":"10.1200\/GO.23.00301","article-title":"Dexamethasone-free antiemetic prophylaxis for highly emetogenic chemotherapy: a double-blind, phase III randomized controlled trial (CINV POD study)","volume":"10","author":"Radhakrishnan","year":"2024","journal-title":"JCO Glob Oncol."},{"key":"2025033118434150400_CIT0031","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"key":"2025033118434150400_CIT0032","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/onco.13680","article-title":"Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy","volume":"26","author":"Janowitz","year":"2021","journal-title":"Oncologist."},{"key":"2025033118434150400_CIT0033","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","article-title":"How to manage patients with corticosteroids in oncology in the era of immunotherapy","volume":"141","author":"Aldea","year":"2020","journal-title":"Eur J Cancer."},{"key":"2025033118434150400_CIT0034","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents","volume":"32","author":"Herrstedt","year":"2023","journal-title":"Support Care Cancer."},{"key":"2025033118434150400_CIT0035","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.acr.2022.02.006","article-title":"Strategies to mitigate the toxicity of cancer therapeutics","volume":"155","author":"Kahn","year":"2022","journal-title":"Adv Cancer Res."},{"key":"2025033118434150400_CIT0036","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","article-title":"Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review","volume":"26","author":"Jordan","year":"2015","journal-title":"Ann Oncol."},{"key":"2025033118434150400_CIT0037","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"112","author":"Yoodee","year":"2017","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025033118434150400_CIT0038","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/bjc.1992.165","article-title":"Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion","volume":"65","author":"Fredrikson","year":"1992","journal-title":"Br J Cancer."},{"key":"2025033118434150400_CIT0039","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/bjc.1996.503","article-title":"5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis","volume":"74","author":"du Bois","year":"1996","journal-title":"Br J Cancer."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf045\/62820279\/oyaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf045\/62820279\/oyaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:22:45Z","timestamp":1743459765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf045\/8101335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf045","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf045"}}